- Home
- STXS vs NTHI Comparison
STXS vs NTHI Comparison
Compare STXS & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STXS | NTHI |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 195.5M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | STXS | NTHI |
|---|---|---|
| Price | $2.37 | $6.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 392.5K | 71.7K |
| Earning Date | 11-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,075,000.00 | $59,990.00 |
| Revenue This Year | $24.48 | N/A |
| Revenue Next Year | $29.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.62 | N/A |
| 52 Week Low | $1.54 | $3.20 |
| 52 Week High | $3.59 | $25.00 |
Technical Indicators
Market Signals| Indicator | STXS | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 37.53 |
| Support Level | $2.31 | $8.63 |
| Resistance Level | $2.42 | $10.44 |
| Average True Range (ATR) | 0.09 | 0.93 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 52.42 | 14.85 |
Price Performance
Historical ComparisonAbout STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).